Stella Diagnostics Announces Completion of Corporate Name and Ticker Symbol Changes (SLDX)
Stella Diagnostics, Inc. (OTC PINK:JMDP) has officially changed its corporate name from JMP Properties, Inc. to Stella Diagnostics, Inc., effective April 16, 2021. Alongside the name change, the company’s common stock will now trade under the new ticker symbol SLDX. This rebranding aligns with the company's mission to enhance patient management strategies for over 67 million individuals suffering from severe esophageal diseases. CEO Dr. Joe Abdo emphasizes that the name and ticker change are crucial for strengthening their brand and mission.
- Corporate name change to Stella Diagnostics enhances brand alignment.
- New ticker symbol SLDX reflects the company's focus on severe esophageal diseases.
- None.
SALT LAKE CITY, UT / ACCESSWIRE / April 16, 2021 / Stella Diagnostics, Inc. (OTC PINK:JMDP) ("Stella" or "The Company") announced today that its corporate name change from "JMP Properties, Inc." to "Stella Diagnostics, Inc." became effective on April 16, 2021. In connection with the name change, the Company's common stock will begin trading on the OTC Markets under the ticker symbol "SLDX" at the open of market trading on April 16, 2021.
"Stella Diagnostics was founded to improve the patient management strategies for the millions of people living with severe esophageal disease," said Stella CEO, Dr. Joe Abdo. "Securing our name and ticker change are important steps in aligning our mission and brand for the betterment of our Company, shareholders, clinical partnerships, and patient care."
About Stella Diagnostics
Stella Diagnostics, Inc. is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX's clinical assay will offer physicians insight into the molecular properties of their patients' tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett's esophagus and esophageal cancer early in the treatment plan may extend or save lives. For more information, please visit www.stelladx.com.
Forward-Looking Statements
Certain statements made in this press release are "forward looking statements" that are based on Stella Diagnostics' beliefs, assumptions, current expectations, estimates and projections. Forward looking statements involve known and unknown risks and uncertainties that may cause forecasted results to differ from actual results. Such risks include, but are not limited to market conditions, competitive factors, the ability to complete the proposed transaction and other such related risks. Stella Diagnostics can give no assurances that any projections related to revenues, profit margins or profits will be realized. Statements that are not historical fact, including without limitation statements which are preceded by, followed by or include the words "believes," "anticipates," "plans," "expects," "estimates," "may," "should," "intends," or similar expressions are forward looking statements. While Stella Diagnostics believes these assumptions, expectations, estimates, and projections are reasonable, such statements are subject to risks and uncertainties, certain of which are beyond our control and therefore, actual results may differ materially. Stella Diagnostics believes that many of the risks detailed here are part of doing business in the industry in which we would operate and compete. Forward looking statements only speak as of the date hereof and we do not undertake and expressly disclaim any obligation to update or release any revisions to any forward-looking statement whether as a result of new information, future events or otherwise except as required by law. While we believe the information used in this press release to be reliable, its accuracy has not been independently verified and cannot be guaranteed. Stella Diagnostics can give no assurances that any projections related to revenues, profit margins or profits will be realized.
Investors and Media Contact:
Stella Diagnostics, Inc.
Email: info@stelladx.com
Phone: 201-381-1474
SOURCE: Stella Diagnostics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/640691/Stella-Diagnostics-Announces-Completion-of-Corporate-Name-and-Ticker-Symbol-Changes-SLDX
FAQ
What is the new ticker symbol for Stella Diagnostics?
When did Stella Diagnostics change its name?
What is the mission of Stella Diagnostics?
How many people are affected by severe esophageal disease according to Stella Diagnostics?
